肝胆相照论坛

标题: 中药(TCM)及其他补充和替代药物(CAM)在慢性乙型肝炎管 [打印本页]

作者: StephenW    时间: 2019-8-20 15:03     标题: 中药(TCM)及其他补充和替代药物(CAM)在慢性乙型肝炎管

Current Hepatology Reports

September 2019, Volume 18, Issue 3, pp 316–321 | Cite as
The Role of Traditional Chinese Medicines (TCM) and Other Complementary and Alternative Medicines (CAM) in the Management of Chronic Hepatitis B

    Authors
    Authors and affiliations

    Guqi WangPeng LiangPing LiYang Hui TanHerbert L. BonkovskyEmail author

    Guqi Wang
        123
    Peng Liang
        4
    Ping Li
        4
    Yang Hui Tan
        5
    Herbert L. Bonkovsky
        1Email author

    1.Section on Gastroenterology & Hepatology, Department of Internal Medicine and Department of Molecular Medicine & Translational SciencesWake Forest University School of MedicineWinston-SalemUSA
    2.Management Committee of Shangrao National Chinese Medicine Health Tourism Demonstration ZoneShangraoChina
    3.Whole Pharm BiotechnologyCharlotteUSA
    4.Beijing Key Lab Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical ScienceChina-Japan Friendship HospitalBeijingChina
    5.Guangzhou Ren Ai Tianhe HospitalGuangzhouChina

Hepatitis B (JK Lim, Section Editor)
First Online: 06 August 2019

    8 Downloads

Part of the following topical collections:

    Topical Collection on Hepatitis B

Abstract
Purpose of Review

To provide a review and update of complementary and alternative medicine (CAM) approaches to the management of chronic hepatitis B, with particular emphasis upon traditional Chinese medicines (TCM).
Recent Findings

The major findings are as follows: (1) TCMs were better than interferons [IFN] in lowering serum HBeAg and normalizing serum ALT, and equivalent to IFN in clearing serum HBV DNA; (2) TCMs were equivalent to lamivudine [LAM] in lowering serum HBeAg, normalizing serum ALT, and clearing serum HBV DNA; (3) TCMs along with IFN or LAM significantly lowered serum HBeAg and improved the clearance of serum HBV DNA and the normalization of serum ALT, compared with IFN or LAM alone; (4) no serious adverse reactions of TCM were reported in all cited clinical trials. Although the composition of traditional medicines in the TCMs varied among RCTs, about 60% of the used herbs were homologous. Our major overarching conclusion was that TCMs seem effective as alternative remedies for patients with CHB. Other CAM approaches also are widely used, especially in east Asian countries, and there is limited evidence of benefit for some.
Summary

CHB continues to be a major health problem worldwide. Although nucleosides such as tenofovir and entecavir are highly effective at suppression of HBV replication, they are expensive and often beyond reach of patients, especially in resource-limited nations and regions. Many such patients will continue to rely upon CAM and TCM for management of their chronic hepatitis B infections. Additional carefully done, placebo-controlled prospective randomized trials of CAM and TCM in chronic hepatitis B should be performed.
Keywords
Chronic infection Complementary and alternative medicines Hepatic cirrhosis Hepatitis B Hepatocellular carcinoma Traditional Chinese medicines
作者: StephenW    时间: 2019-8-20 15:04

目前的肝病学报告

2019年9月,第18卷,第3期,第316-321页引用为
中药(TCM)及其他补充和替代药物(CAM)在慢性乙型肝炎管理中的作用

    作者
    作者和附属机构

    Guqi WangPeng LiangPing LiYang Hui TanHerbert L. Bonkovsky电子书作者

    王古奇
        123
    彭亮
        4
    李平
        4
    杨辉谭
        五
    赫伯特·邦科夫斯基
        1Email作者

    1.内科医学与消化内科,分子医学与转化科学系,森林大学医学院,威斯顿 -  SalemUSA
    上饶中医药健康旅游示范区上饶中国管理委员会
    3.Whole Pharm BiotechnologyCharlotteUSA
    4.北京市重点实验室免疫介导的炎症性疾病研究所临床医学研究所中日友好医院北京中国
    5.广州仁爱天河医院广州中国

乙型肝炎(JK Lim,部门编辑)
首次在线:2019年8月6日

    8下载

以下主题馆藏的一部分:

    关于乙型肝炎的局部收集

抽象
审查目的

提供有关慢性乙型肝炎管理的补充和替代医学(CAM)方法的审查和更新,特别强调中药(TCM)。
最近的调查结果

主要研究结果如下:(1)TCMs在降低血清HBeAg和血清ALT正常方面优于干扰素[IFN],在清除血清HBV DNA方面与IFN相当; (2)TCMs相当于拉米夫定[LAM]降低血清HBeAg,使血清ALT正常化,清除血清HBV DNA; (3)与单独使用IFN或LAM相比,TCM与IFN或LAM一起显着降低血清HBeAg,改善血清HBV DNA清除率和血清ALT正常化; (4)在所有引用的临床试验中均未报告中医的严重不良反应。虽然中医药中传统药物的成分因随机对照试验而异,但大约60%的药草是同源的。我们的主要总体结论是,TCM似乎是CHB患者的替代疗法。其他CAM方法也被广泛使用,特别是在东亚国家,并且一些人受益的证据有限。
摘要

CHB仍然是全球主要的健康问题。尽管替诺福韦和恩替卡韦等核苷类药物在抑制HBV复制方面非常有效,但它们价格昂贵且往往超出患者的范围​​,特别是在资源有限的国家和地区。许多这样的患者将继续依靠CAM和TCM来治疗他们的慢性乙型肝炎感染。应该进行额外的精心实施,安慰剂对照的CAM和TCM在慢性乙型肝炎中的前瞻性随机试验。
关键词
慢性感染补充和替代药物肝硬化乙型肝炎肝细胞癌中药




欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) Powered by Discuz! X1.5